<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285194</url>
  </required_header>
  <id_info>
    <org_study_id>0003M44181</org_study_id>
    <nct_id>NCT00285194</nct_id>
  </id_info>
  <brief_title>hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients</brief_title>
  <official_title>hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The collective effects of two-layer pancreas preservation, pretransplant islet culture, day&#xD;
      -2 pretransplant immunosuppression, and induction immunosuppression with the FcR-nonbinding&#xD;
      anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala)to facilitate diabetes reversal after&#xD;
      single-donor islet transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, one-year follow-up study of type 1 diabetic islet allograft recipients&#xD;
      who receive FcR non-binding OKT3 antibody hOKT3γ1 (Ala-Ala) plus sirolimus induction&#xD;
      immunotherapy combined with sirolimus and delayed tacrolimus maintenance immunosuppression.&#xD;
      Six subjects were transplanted.&#xD;
&#xD;
      The premise behind the proposal is that hOKT3γ1(Ala-Ala) corrects the imbalance between&#xD;
      autoreactive and regulatory T cells and consequently prevents autoimmune destruction of&#xD;
      transplanted islets. To prevent allorejection, hOKT3γ1(Ala-Ala)was combined with sirolimus&#xD;
      and delayed tacrolimus. Additionally, the safety and efficacy of the maintenance&#xD;
      immunosuppressive regimen of sirolimus combined with tacrolimus was monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, tolerability, immune activity, and pharmacokinetics of hOKT3γ1 (Ala-Ala) antibody induction therapy for the prevention of autoimmune destruction and rejection of allogeneic islet transplants as measured by:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Physical examination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Vital signs</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Body weight</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Laboratory and diagnostic safety assessments included complete blood counts with differential and platelets, circulating T cell phenotypes, and serum chemistry.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-Immune activity and pharmacokinetic assessments included hOKT3γ1 (Ala-Ala) level and half-life, monoclonal antibody coating and modulation of CD3 on peripheral blood T cells, and anti-hOKT3γ1 (Ala-Ala) antibody responses.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of hOKT3γ1 (Ala-Ala) antibody induction therapy for the prevention of autoimmune destruction and rejection of islet transplants as defined by:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Proportion of subjects with full islet graft function (insulin independence and HbA1c &lt;7%);</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Proportion of subjects with partial islet graft function (insulin dependence, basal or arginine-stimulated C-peptide levels of greater or equal to 0.5 ng/ml and HbA1c &lt;7%);</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Proportion of subjects with slet graft loss will be defined as a return to insulin therapy for &gt;30 days, absence of basal and arginine-stimulated C-peptide, re-transplantation, or patient death;</measure>
  </secondary_outcome>
  <enrollment>6</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic Islets of Langerhans</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hOKT3γ1 (Ala-Ala)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary islet allotransplant&#xD;
&#xD;
          2. Type 1 diabetes mellitus, complicated by at least one of the following situations that&#xD;
             persist despite intensive efforts in close cooperation with their diabetes care team:&#xD;
&#xD;
               1. Metabolic lability/instability;&#xD;
&#xD;
               2. Reduced awareness of hypoglycemia;&#xD;
&#xD;
               3. Persistently poor glucose control (as defined by HgbA1c&gt;10% at the end of six&#xD;
                  months of intensive management efforts with the diabetes care team);&#xD;
&#xD;
               4. Progressive secondary complications.&#xD;
&#xD;
          3. Age 18 and older&#xD;
&#xD;
          4. Able to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than 18 years&#xD;
&#xD;
          2. Body weight greater than75 kg.&#xD;
&#xD;
          3. BMI greater than 26 kg/m2 for male and females&#xD;
&#xD;
          4. Waist-to-hip ratio 0.80 (female) and 0.95 (male)&#xD;
&#xD;
          5. First degree relative with type 2 diabetes&#xD;
&#xD;
          6. Insulin requirement of greater than 0.7 IU/kg/day&#xD;
&#xD;
          7. HbA1C greater than 12%&#xD;
&#xD;
          8. Positive C-peptide response to intravenous arginine stimulation&#xD;
&#xD;
          9. Untreated proliferative retinopathy&#xD;
&#xD;
         10. Macroalbuminuria (urinary albumin excretion greater than 300 mg/24hrs)&#xD;
&#xD;
         11. Creatinine clearance greater than 85 ml/min/1.73 m2 in females, greater than 95&#xD;
             ml/min/1.73 m2 in males&#xD;
&#xD;
         12. Serum creatinine greater than 1.2 mg/dl&#xD;
&#xD;
         13. Previous pancreas or islet transplant&#xD;
&#xD;
         14. Previous OKT3 antibody therapy&#xD;
&#xD;
         15. Presence of history of panel-reactive anti-HLA antibodies greater than 10%&#xD;
&#xD;
         16. Abnormal T4 and TSH despite thyroid replacement therapy&#xD;
&#xD;
         17. Positive pregnancy test, or presently breast-feeding&#xD;
&#xD;
         18. Active infection&#xD;
&#xD;
         19. Negative screen for Epstein-Barr Virus (EBV) by an EBNA method&#xD;
&#xD;
         20. Invasive aspergillus infection within year prior to study entry&#xD;
&#xD;
         21. Any history of malignancy&#xD;
&#xD;
         22. Active alcohol or substance abuse&#xD;
&#xD;
         23. History of non-adherence to prescribed regimens&#xD;
&#xD;
         24. Psychiatric disorder making the subject not a suitable candidate for transplantation&#xD;
&#xD;
         25. Karnofsky performance score greater than 70&#xD;
&#xD;
         26. Baseline Hgb greater than 11.7 g/dl; lymphopenia (greater than 1,000/L), or leukopenia&#xD;
             (greater than 4,000 total leukocytes/L), or an absolute CD4+ count &lt;500/L&#xD;
&#xD;
         27. Thrombocytopenia greater than 150 x 109/L&#xD;
&#xD;
         28. Use of warfarin or other anticoagulant therapy (except aspirin) or patient with PT-INR&#xD;
             greater than 1.5&#xD;
&#xD;
         29. Severe co-existing cardiac disease&#xD;
&#xD;
         30. Baseline liver function tests outside of normal range&#xD;
&#xD;
         31. Presence of gallstones on baseline ultrasound exam&#xD;
&#xD;
         32. Active peptic ulcer disease&#xD;
&#xD;
         33. Severe unremitting diarrhea or other gastrointestinal disorders potentially&#xD;
             interfering with the ability to absorb oral medications&#xD;
&#xD;
         34. Celiac disease&#xD;
&#xD;
         35. Hyperlipidemia (fasting LDL cholesterol greater than 130 mg/dl, treated or untreated;&#xD;
             and/or fasting triglycerides greater than 200 mg/dl)&#xD;
&#xD;
         36. Addison's disease.&#xD;
&#xD;
         37. Under treatment for a medical condition requiring chronic use of systemic steroids&#xD;
&#xD;
         38. Any medical condition that, in the opinion of the investigator, will interfere with&#xD;
             the safe completion of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard J. Hering, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universtiy of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004 Mar;4(3):390-401.</citation>
    <PMID>14961992</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>January 30, 2006</study_first_submitted>
  <study_first_submitted_qc>January 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

